nach oben

Erschienen in:

03.05.2014 | Original Article

Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients

verfasst von: Lourdes Mateo, Susana Holgado, Maria Luisa Mariñoso, Ricard Pérez-Andrés, Anna Bonjoch, Joan Romeu, Alejandro Olivé

Erschienen in: Clinical Rheumatology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Tenofovir disoproxil fumarate (TDF) is an adenine analogue reverse transcription inhibitor widely used in first-line treatment of human immunodeficiency virus (HIV) infection and also in hepatitis B virus infection. Its use has been linked to sporadic Fanconi syndrome, renal failure and bone disease. We present the clinical characteristics of tenofovir-induced osteomalacia, discuss bone biopsy findings, describe predisposing factors and compare our results with other reported cases. We describe five cases of hypophosphatemic osteomalacia induced by TDF and recorded at the rheumatology service of a university hospital between 2010 and 2014. We also report the characteristics of bone biopsies of this pathology, which have not been previously described. We include a review of published cases of proximal renal tubulopathy (PRT) and osteomalacia induced by TDF (PubMed 1995–2014; keywords: osteomalacia, tenofovir, Fanconi syndrome, hypophosphatemic osteomalacia, proximal renal tubulopathy, bone biopsy). Five HIV patients who developed hypophosphatemic osteomalacia under TDF treatment (>5 years) presented increasing bone pain and a progressive inability to walk without assistance as a result of multiple insufficiency fractures. Bone biopsy performed in three patients after tetracycline labelling showed increased osteoid thickness, confirming osteomalacia. A literature review retrieved 17 publications on this condition, including 53 cases: 26 patients developed isolated PRT, 25 presented PRT and with multiple insufficiency fractures and two presented isolated bone disease, including osteomalacia and osteoporosis. Rheumatologists should be alert to this complication in patients receiving tenofovir. The main complaint reported by these patients is diffuse pain, predominantly in the lower limbs, indicating multiple stress fractures. Serum phosphate and appropriate screening for abnormal proximal tubule function should be monitored. Bone scintigraphy should be carried out in cases of limb pain before the occurrence of more severe complications.

Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17(13):1917–1923CrossRefPubMed

Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20(17):2165–2174CrossRefPubMed

Cotter AG, Powderly WG (2011) Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab 25(3):501–515CrossRefPubMed

Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L et al (2010) High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24(18):2827–2833CrossRefPubMed

Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V et al (2005) Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 20(4):743–746CrossRefPubMed

Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G (2006) Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 42(2):283–290CrossRefPubMed

Saidenberg-Kermanac’h N, Souabni L, Prendki V, Prie D, Boissier MC (2011) Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. Joint Bone Spine 78(3):306–308CrossRefPubMed

Haverkort ME, van der Spek BW, Lips P, Slieker WA, ter Heine R, Huitema AD et al (2011) Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature. Scand J Infect Dis 43(10):821–826CrossRefPubMed

Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J et al (2009) Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 23(6):689–696CrossRefPubMed

10.

Kinai E, Hanabusa H (2009) Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retrovir 25(4):387–394CrossRefPubMed

11.

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD et al (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292(2):191–201CrossRefPubMed

12.

Coca S, Perazella MA (2002) Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 324(6):342–344CrossRefPubMed

13.

Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D et al (2009) Tenofovir-associated renal and bone toxicity. HIV Med 10(8):482–487CrossRefPubMed

14.

Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM et al (2004) Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35(3):269–273CrossRefPubMed

15.

Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK et al (2004) Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 18(7):1074–1076CrossRefPubMed

16.

Jhaveri MA, Mawad HW, Thornton AC, Mullen NW, Greenberg RN (2010) Tenofovir-associated severe bone pain: I cannot walk! J Int Assoc Phys AIDS Care (Chic) 9(5):328–334CrossRef

17.

Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne C (2009) Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol 15(2):72–74CrossRefPubMed

18.

Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS (1999) Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56(2):383–389PubMed

19.

Bonjoch A, Echeverria P, Perez-Alvarez N, Puig J, Estany C, Clotet B et al (2012) High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Res 96(1):65–69CrossRefPubMed

20.

Earle KE, Seneviratne T, Shaker J, Shoback D (2004) Fanconi’s syndrome in HIV + adults: report of three cases and literature review. J Bone Miner Res 19(5):714–721CrossRefPubMed

21.

Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW (2005) The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 6(5):341–346CrossRefPubMed

22.

De la Prada FJ, Prados AM, Tugores A, Uriol M, Saus C, Morey A (2006) Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir. Nefrologia 26(5):626–630PubMed

23.

Torres Isidro MV, Garcia Benayas T, del Val Gomez Martinez M, Gonzalez Gallardo F, Gambi Pisonero N, Castilla Miguel S et al (2006) Role of bone gammagraphy in the diagnosis of secondary osteomalacia in a patient treated with tenofovir. Rev Esp Med Nucl 25(2):103–106CrossRefPubMed

24.

Rosello L, Gort A, Planella R, Cabau J (2007) Hypophosphatemia and multiple fractures in patient with human immunodeficiency virus infection treated with tenofovir. Med Clin (Barc) 129(5):197CrossRef

25.

Brim NM, Cu-Uvin S, Hu SL, O’Bell JW (2007) Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome. AIDS Read 17(6):322–328, C3PubMed

26.

Di Biagio A, Rosso R, Monteforte P, Russo R, Rovetta G, Viscoli C (2009) Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. J Med Case Rep 3:8136CrossRefPubMedPubMedCentral

27.

Wanner DP, Tyndall A, Walker UA (2009) Tenofovir-induced osteomalacia. Clin Exp Rheumatol 27(6):1001–1003PubMed

28.

Izzedine H, Thibault V, Valantin MA, Peytavin G, Schneider L, Benhamou Y (2010) Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence? AIDS 24(7):1078–1079CrossRefPubMed

29.

Perez-Rivera AA, Saez P, Leon E, Lozano de Leon-Naranjo F (2011) HIV infected women with intense bone and muscular pain and general weakness. Enferm Infecc Microbiol Clin 29(4):308–310CrossRefPubMed

30.

De Socio GV, Fabbriciani G, Massarotti M, Messina S, Cecchini E, Marasini B (2012) Hypophosphatemic osteomalacia associated with tenofovir: a multidisciplinary approach is required. Mediterr J Hematol Infect Dis 4(1):e2012025CrossRefPubMedPubMedCentral

31.

Lucey JM, Hsu P, Ziegler JB (2013) Tenofovir-related Fanconi’s syndrome and osteomalacia in a teenager with HIV. BMJ Case Rep 9:2013

32.

Koenig KF, Kalbermatter S, Menter T, Graber P, Kiss D (2014) Recurrent bone fractures due to tenofovir-induced renal phosphate wasting. Scand J Infect Dis 46(3):221–224CrossRefPubMed

33.

Gómez Martinez MV, Gallardo FG, Pirogova T, García-Samaniego J (2014) Bone scintigraphy and secondary osteomalacia due to nephrotoxicity in a chronic hepatitis B patient treated with tenofovir. Rev Esp Med Nucl Imagen Mol 33(2):103–105PubMed

34.

Hamnvik OP, Becker CB, Levy BD, Loscalzo J (2014) Wasting away. N Engl J Med 370:959–966CrossRefPubMed

35.

Hall AM, Hendry BM, Nitsch D, Connolly JO (2011) Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 57(5):773–780CrossRefPubMed

36.

Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA et al (2005) Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40(11):1559–1585CrossRefPubMed

Titel: Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients
verfasst von: Lourdes Mateo
Susana Holgado
Maria Luisa Mariñoso
Ricard Pérez-Andrés
Anna Bonjoch
Joan Romeu
Alejandro Olivé
Publikationsdatum: 03.05.2014
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 5/2016
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-014-2627-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome

Prevalence of musculoskeletal symptoms in the five urban regions of Brazil—the Brazilian COPCORD study (BRAZCO)

Hyaluronic acid and glucosamine sulfate for adult Kashin-Beck disease: a cluster-randomized, placebo-controlled study

Determinants of methotrexate adherence in rheumatoid arthritis patients

Is entheses ultrasound reliable? A reading Latin American exercise